Indicaton

Infectious diseases

Debio 4028 program leverages the immunomodulatory, pro-apoptotic and virus-reactivating properties of a new generation of potent, orally available Inhibitor of Apoptosis Proteins (IAP) antagonists to cure various chronic infectious diseases. These new molecules are expected to allow the discontinuation of any antiviral treatment and eliminate the risk of clinical relapse, transmission of the infection and long-term complications.

Therapeutic indications
Type of product
Table
  • Phase
    Discovery
  • Partnering status
    Not partnered